OSP News

Updated Guidelines on Cholesterol Management

Posted: 02/05/2019

Key recommendations from the new guidelines on cholesterol management include:

  • For patients with established ASCVD, high-intensity statins should be used to obtain ≥50% reduction in LDL. If this is not achieved, ezetimibe could be added and then a proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor.
  • For patients with very high risk (history of major ASCVD events, older age, diabetes, hypertension, smoking, familial hypercholesterolemia [FH], kidney disease, or heart failure) and LDL levels >70 mg/dL, adding ezetimibe is reasonable, followed by a PCSK9 inhibitor.
  • For patients with severe hypercholesterolemia (LDL levels, >190 mg/dL), maximally tolerated statin therapy is recommended without risk calculations. If LDL is not reduced by 50%, clinicians can reasonably add ezetimibe.
  • For patients with diabetes and LDL >70 mg/dL, a moderate-intensity statin is recommended; with elevated ASCVD risk, a high-intensity statin is reasonable.
  • For primary prevention, adherence to a healthy lifestyle is the cornerstone of treatment across the lifespan. Clinician-patient discussions about risk assessment and treatment should consider “ASCVD risk enhancers,” such as family history, metabolic history, preeclampsia, inflammatory disease, ethnicity, and abnormal biomarkers.
  • 10-year ASCVD risk scores between 7.5% and 19.9% are now considered “intermediate risk.” This broad category acknowledges uncertainty in risk-calculator estimates and is intended to encourage decision-making guided by patient preferences. For patients who elect drug treatment, a moderate-intensity statin is generally recommended.
  • Coronary artery calcium (CAC) measurement is helpful when decisions about statin initiation are uncertain. Withholding or postponing statin initiation is reasonable if CAC=0 and the patient lacks other high-risk features. If CAC score is ≥100, statins should be initiated.
  • To monitor adherence to therapy and reduction in LDL, clinicians should check lipids 1 to 3 months after a treatment change.

Click here for the full guideline.

We value your privacy. We use cookies and other technologies to keep the web site reliable and secure, tailor your experience, and measure web site performance, as described in our Privacy Policy.

x

OSP Technical Support